Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.10. rezultāts no 100.
400. lappuse
... peak ( at a retention time equal to that observed for the clindamycin palmitate hydrochloride standard ) / Area of internal standard peak ; R - Area of the clindamycin palmitate hy- drochloride standard peak / Area of in- ternal standard ...
... peak ( at a retention time equal to that observed for the clindamycin palmitate hydrochloride standard ) / Area of internal standard peak ; R - Area of the clindamycin palmitate hy- drochloride standard peak / Area of in- ternal standard ...
401. lappuse
... peak ( at a retention time equal to that ob- served for the clindamycin standard ) / Area of internal standard peak ; Ru - Area of the clindamycin standard peak / Area of internal standard peak ; W , Weight of the clindamycin working ...
... peak ( at a retention time equal to that ob- served for the clindamycin standard ) / Area of internal standard peak ; Ru - Area of the clindamycin standard peak / Area of internal standard peak ; W , Weight of the clindamycin working ...
402. lappuse
... peak and to maintain a stable base line . The resolution of the peaks should be complete . The elution order is lincomycin B , lincomycin , and the internal standard . If necessary , ad- just the current setting for the linco- mycin B peak ...
... peak and to maintain a stable base line . The resolution of the peaks should be complete . The elution order is lincomycin B , lincomycin , and the internal standard . If necessary , ad- just the current setting for the linco- mycin B peak ...
403. lappuse
... peak . The resolu- tion of the peaks should be complete . The internal standard will be eluted be- fore ... peak ( at a retention time equal to that observed for the spectinomycin standard ) / Area of internal standard peak ; R = Area of ...
... peak . The resolu- tion of the peaks should be complete . The internal standard will be eluted be- fore ... peak ( at a retention time equal to that observed for the spectinomycin standard ) / Area of internal standard peak ; R = Area of ...
413. lappuse
... peaks should be complete . The griseofulvin peak will elute before the internal standard peak . Calculate the griseofulvin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the griseo- fulvin ...
... peaks should be complete . The griseofulvin peak will elute before the internal standard peak . Calculate the griseofulvin content as directed in paragraph ( f ) of this section . ( f ) Calculations . Calculate the griseo- fulvin ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning